“The painkillers market will reach $68.2 billion in 2014 according to new Visiongain report”

LONDON - Sept. 19, 2014 - PRLog -- The emergence of promising drug candidates and innovative technologies over the last decade has helped the pain relieving drugs market to achieve substantial growth. The development of new drugs, reformulations of existing products, and the advancements being made in drug delivery technologies will help to stimulate the market for pain relieving drugs over the next decade. The pain relieving drugs market comprises of many drugs classed into various categories. These include narcotics such as Oxycontin ER, Duragesic, and Ultram, and drugs for neuropathic pain such as Lyrica, Cymbalta, and Nucynta. Also included in this market are anti-migraine drugs such as Axert and Relpax, and anti-arthritis drugs such as Humira, Enbrel, and Voltaren.

Moses Akintomide-Akinwamide, a senior pharmaceutical and medical technology market analyst at Visiongain comments: “The rising incidence and prevalence of pain episodes in the increasingly ageing global population is a factor contributing to the growth of the pain relieving drugs market. However, the side effect profiles of pain relieving drugs - such as the cardiac side effects which have been reported for Celebrex – means that stringent monitoring is required for some drugs during their use. Gastrointestinal side effects such as oesophageal, gastric and duodenal ulceration which is associated with many non-steroidal anti-inflammatory drugs (NSAIDS) may act as a restraint to growth in the market. The tolerance and dependence issues which are notoriously associated with opioid pain relieving drugs in particular may also act to hinder growth in the market over the next decade. However, the leading anti-arthritic biologics will continue to generate high revenues despite the expiry of some of their patents as the expected slow uptake of biosimilars means that these expiries will impact less on the sales of these biologics over the next decade.”

The reforms in some sectors of the pain relieving drugs market, like narcotics, offer growth opportunities. “New reformulated tamper-resistant versions of top sellers such as Oxycontin and Opana ER are being developed and introduced into the market. These measures should allay the fears of physicians who have been reluctant to prescribe these drugs, especially in high doses”, Moses added.

Visiongain’s 323 page report provides revenue forecasts to 2024 for the global pain relieving drugs market and its leading regional markets. The new study includes OTC (over-the counter) and Rx (prescription) pain relieving medicines.  It forecasts sales in 13 leading markets, the US, Japan, Germany, France, Italy, Spain, UK, China, India, Russia, Brazil, South Korea, and Turkey. The report also forecasts sales for subsectors of the pain relieving drugs market. These include the anti-arthritic, narcotic, neuropathic, anti-migraine, and non-narcotic segments of the market. Analysis and forecasts for key marketed products in each of these segments are provided together with profiles and analysis of products in the development pipeline. The new investigation predicts revenues of 28 leading drugs in the painkillers market, including Oxycontin ER, Panadol, Lyrica and Zomig. Research, data and analyses cover activities of Pfizer, GSK, Johnson and Johnson, Bristol-Myers Squibb and other pharmaceutical companies.

The report also includes analysis of strengths, weaknesses, opportunities and threats to the market, an analysis of the social, technological, economical, and political factors that will influence the market, together with interviews with key opinion leaders in the industry sharing their views on current market trends and the unmet needs in the market.

Pain Relieving Drugs Market Forecast 2014-2024: Future Prospects For Leading Companies adds to visiongain’s extensive range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the Visiongain report Pain Relieving Drugs Market Forecast 2014-2024 please visit https://www.visiongain.com/Report/1319/Pain-Relieving-Dru...

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.